RespiDx

Company Overview

Snapshot

Founded in March 2015 by Dr. Keren Fradkin, Amir Elhasid, Prof. Israel Amirav, and Ian Solomon, RespiDx operated with 1-10 employees. The company ceased operations in May 2019.

Business overview

RespiDx is a social impact venture focused on developing diagnostic solutions for pneumonia and febrile diseases in low-resource settings. The company's core product, the Multimometer, is designed to enable simple, automatic diagnosis of pneumonia based on World Health Organization criteria by untrained community health workers. RespiDx primarily serves global health initiatives and aims to adapt its technology for telemedicine applications in developed markets, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Medical Diagnostics.

Company Intelligence Q&A

What is the primary product developed by RespiDx?

RespiDx developed the Multimometer, a device designed for the simple diagnosis of pneumonia and febrile disease in the field by untrained community health workers, based on World Health Organization diagnostic criteria.

When did RespiDx cease its operations?

RespiDx ceased to operate in May 2019.

What was the focus of RespiDx's activities prior to ceasing operations?

RespiDx's activities were focused on optimizing the Multimometer for mass manufacturing and market entry, with clinical studies performed in the Democratic Republic of the Congo.

Which organizations supported RespiDx's work in diagnosing pneumonia in underdeveloped countries?

RespiDx's activities were supported by Grand Challenges Israel, USAid, and Grand Challenges Canada.

What was the purpose of the USAID grant received by RespiDx?

In March 2016, RespiDx received a $150,000 grant from USAID to further develop its Respimometer for diagnosing childhood pneumonia in low-resource regions, covering manufacturing of up to 200 Respimometers and a trial in the Democratic Republic of the Congo.